{
  "docId": "019de074-1317-767b-825b-77b5f795fc6c",
  "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 44,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide includes a list of authors for a related longitudinal analysis.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/29",
  "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
  "deckJsonHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c.json",
  "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.82,
        "x": 0.115,
        "y": 0.0064
      },
      "kind": "list",
      "text": "Roy Freeman1, Italo Biaggioni2, Ross Vickery3, Lucy Norcliffe-Kaufmann4, Tadhg Guerin5, Rajeev Saggar5, Lydia Lopez Manzanares6, Valeria Iodice7, Monika Rudzińska-Bar8, Maria Teresa Pellecchia9, Horacio Kaufmann4",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "560ef9a5-0481-4c04-9a9e-e4644bb5e0fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.91,
        "x": 0.042,
        "y": 0.0015
      },
      "kind": "list",
      "text": "Ampreloxetine demonstrated trend for benefit in the primary and key secondary endpoints in the prespecified MSA subgroup\nAmpreloxetine was generally well tolerated\nThese results encouraged us to perform a longitudinal analysis in the subset of patients with MSA",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7385b0be-dc3c-4948-a9a3-b5b70ea6385b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.77,
        "x": 0.115,
        "y": 0.0047
      },
      "kind": "paragraph",
      "text": "Longitudinal analysis of ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension in subset of patients with multiple system atrophy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8876f854-9741-46af-aa47-d0e24d749f60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.23,
        "x": 0.042,
        "y": 0.045
      },
      "kind": "title",
      "text": "Conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7dab89a-149d-434a-847f-d75008edf1e5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "bcb6bd4b-d9c7-47e4-9b3a-0f1137401ab9",
      "evidence": "The slide contains list/bullet components summarizing conclusions.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}